



## CHDI-90004508: Anti-PolyQ Antibody Amino Acid Sequence

### **DISCLAIMER**

THE INFORMATION DISPLAYED BELOW WAS GENERATED SOLELY BY CHDI FOUNDATION, INC. (CHDI) FROM THE 1G101G12 (MW1) HYBRIDOMA PROVIDED TO CHDI BY THE CALIFORNIA INSTITUTE OF TECHNOLOGY (CALTECH). CALTECH WAS NOT INVOLVED IN THE GENERATION OF THE INFORMATION DISPLAYED BELOW AND THE SHARING OF THE INFORMATION BELOW IS DONE SOLELY OF CHDI'S ACCORD.

THE INFORMATION DISPLAYED BELOW IS PROVIDED "AS-IS". NEITHER CHDI NOR CALTECH MAKES ANY REPRESENTATIONS OR WARRANTIES OF ANY KIND CONCERNING THE INFORMATION DISPLAYED BELOW AND EACH OF CHDI AND CALTECH HEREBY DISCLAIMS ALL REPRESENTATIONS, WARRANTIES AND CONDITIONS, EXPRESS OR IMPLIED, INCLUDING THOSE OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NONINFRINGEMENT OF INTELLECTUAL PROPERTY RIGHTS AND THE ABSENCE OF LATENT OR OTHER DEFECTS, WHETHER OR NOT DISCOVERABLE. EACH OF CHDI AND CALTECH FURTHER EXPRESSLY DISCLAIMS ANY WARRANTY REGARDING RESULTS OBTAINED THROUGH THE USE OF THE INFORMATION DISPLAYED BELOW, INCLUDING ANY CLAIM OF INACCURATE, INVALID OR INCOMPLETE RESULTS. IN NO EVENT SHALL CHDI, CALTECH OR ANY OF THEIR RESPECTIVE DIRECTORS, TRUSTEES, OFFICERS, EMPLOYEES, AGENTS OR SERVICES PROVIDERS BE LIABLE FOR INCIDENTAL OR CONSEQUENTIAL DAMAGES OF ANY KIND, INCLUDING ECONOMIC DAMAGES OR INJURY TO PROPERTY AND LOST PROFITS OR REVENUES, REGARDLESS OF WHETHER CHDI OR CALTECH SHALL BE ADVISED, SHALL HAVE OTHER REASON TO KNOW, OR IN FACT SHALL KNOW OF THE POSSIBILITY OF THE FOREGOING.

CHDI WILL NOT BRING ANY ACTION AGAINST ANY USER OF THE INFORMATION DISPLAYED BELOW BASED UPON THE INFRINGEMENT OF CHDI'S INTELLECTUAL PROPERTY RIGHTS. HOWEVER, THE PROVISION OF THE INFORMATION DISPLAYED BELOW DOES NOT CONSTITUTE THE GRANT OF ANY LICENSE, EXPRESS OR IMPLIED, UNDER ANY INTELLECTUAL PROPERTY RIGHT HELD BY ANY OTHER PERSON OR ENTITY (INCLUDING CALTECH).

ANY PERSON OR ENTITY USING, OR HAVING USED, THE INFORMATION DISPLAYED BELOW EXPRESSLY AGREES THAT THE USE OF THE INFORMATION DISPLAYED BELOW IS AT THEIR SOLE RISK.

### **Heavy Chain Sequence**

MNLGLSLIFLVLVKGVQCEVKLVESGGGLVQPGGSLKLSCAASGFTFRDYMYWVRQTPEKRLEWVAFISNGGGSTYYPDTVKGRT  
ISRDNAKNTLYLQMSRLKSEDTAMYCARGRGYVWFAYWGQGLVTVSAAKTTPPSVYPLAPGCGDTTGSSVTLGCLVKGYFPESVT  
VTWNSGSLSSSVHTFPALLQSGLYTMSSSVTPSSTWPSQVTCTCSVAHPASSTTVDDKLEPSGPSTINPCPPCKECHKCPAPNLEGGP  
SVFIFPPNIKDVLMIPLTPKVTCTVVDVSEDDPDVRISWVNNVEVHTAQQTQTHREDYNSTIRVVSALPIQHQDWMSGKEFKCKVNN  
KDLPSPIERTISKIKGLVRAPQVYILPPPAEQLSRKDVSLTCLVVGFNPGDISVEWTSNGHTEENYKDTAPVLDSGSGYFIYSKLDIKTSKW  
EKTDSFSCNVRHEGLKNYYLKKTISRSPGK

### **Light Chain Sequence**

MAWTPLFFFFVLHCSGSFSQLVLTQSSSASFSLGASAKLTCTLSSQHSITYIEWYQQQLPKPKYVMELKKDGSHSTGDGIPDRFSGSS  
SGADRYLSISNIQPEDEAIYICGVGDTIKEQFVYVFGGGTKVTVLGQPKSTPTLTVPFPPSSEELKENKATLVCLISNFPSPGVTVAWKANG  
TPITQGVDTSNPTKEGNKFMASFLHLTSDQWRSHNSFTCQVTHEGDTV EKSLSPAEL

August 19, 2025